← Ireland

S.I. No. 402/2022 - Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 4) Regulations 2022

S.I. No. 402/2022 - Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 4) Regulations 2022 Skip to content Disclaimer Feedback Helpdesk Gaeilge Léim go dtí an t-ábhar Séanadh Aiseolas Deasc chabhrach English Gaeilge English Produced by the Office of the Attorney General Táirgthe ag Oifig an Ard-Aighne Home Legislation Acts of the Oireachtas Statutory Instruments Pre-1922 Legislation Constitution External Resources Bills (Houses of the Oireachtas) Iris Oifigiúil / Official Gazette Revised Acts (LRC) Classified List of Legislation (LRC) Translations (acts.

  1. ie)Translations (Houses of the Oireachtas) Government Publications for Sale EU Law (EUR-Lex) FAQ Disclaimer Feedback Helpdesk Search Baile Reachtaíocht Achtanna an Oireachtais Ionstraimí Reachtúla Reachtaíocht Réamh-1922 Bunreacht Acmhainní Seachtracha Billí (Tithe an Oireachtais) Iris Oifigiúil Achtanna Athbhreithnithe (CAD) (An Coimisiún um Athchóiriú an Dlí) Liosta Rangaithe Reachtaíochta Aistriúcháin (achtanna.
  2. ie)Aistriúcháin (Tithe an Oireachtais) Foilseacháin Rialtais ar Díol Dlí AE (EUR-Lex) CCanna (Ceisteanna Coitianta) Séanadh Aiseolas Deasc chabhrach Cuardach TitleTeideal Year(
  3. s)or rangeBliain nó blianta nó raon TypeCineál All Legislation Acts Statutory Instruments Advanced SearchCuardach Casta HomeBaile Statutory InstrumentsIonstraimí Reachtúla 2022 S.I. No. 402/2022 - Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 4) Regulations 2022 S.I. No. 402/2022 - Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 4) Regulations 2022 AmendmentsLeasuithe Download PDF Íoslódáil PDF Notice of the making of this Statutory Instrument was published in “Iris Oifigiúil” of 2nd August, 2022. I, STEPHEN DONNELLY, in exercise of the powers conferred on me by section 32 (as amended by section 16 of the Irish Medicines Board (Miscellaneous Provisions) Act 2006 (No. 3 of 2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make the following regulations: 1.

(1)These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 4) Regulations 2022.
(2)The collective citation “the Medicinal Products (Prescription and Control of Supply) Regulations 2003 to 2022” includes these Regulations. 2. In these Regulations— “Principal Regulations” means the Medicinal Products (Prescription and Control of Supply) Regulations 2003 ( S.I. No. 540 of 2003 ); “Regulations of 2022” means the Medicinal Products (Prescription and Control of Supply (Amendment) (No. 3) Regulations 2022 ( S.I. No. 84 of 2022 ). 3. The Eighth Schedule (as amended by Regulation 3 of the Regulations of 2022) to the Principal Regulations is amended— (
  1. a)in column 5 of the entry for the medicinal product “Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)”, by substituting “pregnancy, living arrangements or otherwise” for “pregnancy or otherwise”, (
  2. b)in column 5 of the entry for the medicinal product “Spikevax (previously Covid-19 Vaccine Moderna) dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)”, by substituting “pregnancy, living arrangements or otherwise” for “pregnancy or otherwise”, and (
  3. c)by substituting for the text in column 5 of the entry for the medicinal product “Comirnaty 10 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) Paediatric pack” the following: “In accordance with relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health, subject to informed consent being obtained from a parent or guardian. Administered as a course of 2 doses (0.2 mL each) at least 19 days apart. An additional dose should be administered to children aged 5 to 11 years who are immunocompromised at least 28 days after the second dose to complete the primary series. Notwithstanding any directions to the contrary in the summary of product characteristics, a booster dose may be administered to children aged 5 to 11 years who— (
  4. a)are immunocompromised and have already received an additional dose of a Covid-19 vaccine, or (
  5. b)have already received a primary vaccine course against Covid-19 and have become immunocompromised since the administration of that primary vaccine course. The additional and booster doses should be administered in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, immune status, living arrangements or otherwise), as may be specified in such recommendations or guidelines.”. 4. The Twelfth Schedule (as amended by Regulation 4 of the Regulations of 2022) to the Principal Regulations is amended— (
  6. a)in column 5 of the entry for the medicinal product “Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)”, by substituting “pregnancy, living arrangements or otherwise” for “pregnancy or otherwise”, (
  7. b)in column 5 of the entry for the medicinal product “Spikevax (previously Covid-19 Vaccine Moderna) dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified)”, by substituting “pregnancy, living arrangements or otherwise” for “pregnancy or otherwise”, and (
  8. c)by substituting for the text in column 5 of the entry for the medicinal product “Comirnaty 10 micrograms/dose concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) Paediatric pack” the following: “In accordance with relevant recommendations or guidelines issued by the National Immunisation Advisory Committee and accepted by the Minister for Health, subject to informed consent being obtained from a parent or guardian. Administered as a course of 2 doses (0.2 mL each) at least 19 days apart. An additional dose should be administered to children aged 5 to 11 years who are immunocompromised at least 28 days after the second dose to complete the primary series. Notwithstanding any directions to the contrary in the summary of product characteristics, a booster dose may be administered to children aged 5 to 11 years who— (
  9. a)are immunocompromised and have already received an additional dose of a Covid-19 vaccine, or (
  10. b)have already received a primary vaccine course against Covid-19 and have become immunocompromised since the administration of that primary vaccine course. The additional and booster doses should be administered in such volumes, at such intervals, in such manner and in such order of prioritisation (whether by reference to age, immune status, living arrangements or otherwise), as may be specified in such recommendations or guidelines.”. GIVEN under my Official Seal, 29 July, 2022. STEPHEN DONNELLY, Minister for Health. EXPLANATORY NOTE (This note is not part of the Instrument and does not purport to be a legal interpretation.) These Regulations amend the Medicinal Products (Prescription and Control of Supply) Regulations 2003. The purpose of these Regulations is to amend the relevant schedules in relation to the COVID-19 vaccines to provide for booster doses of Comirnaty COVID-19 Vaccine, Paediatric Formulation to immunocompromised persons aged 5 to 11 and to clarify that booster doses of the mRNA vaccines may be prioritised on the basis of living arrangements. These Regulations may be cited as the Medicinal Products (Prescription and Control of Supply) (Amendment) (No. 4) Regulations 2022. Privacy Statement Accessibility European Legislation Identifier (PDF) Open Data License Ráiteas Príobháideachais Inrochtaineacht Aitheantóir Eorpach Reachtaíochta (ELI) Ceadúnas Sonraí Oscailte Liosta Fianán © Government of Ireland. Oireachtas Copyright Material is reproduced with the permission of the Houses of the Oireachtas © Rialtas na hÉireann. Atáirgtear ábhar faoi Chóipcheart le cead ó Thithe an Oireachtais

🔗 To official source

AI explanation based on the official legal text. Indicative, not a substitute for legal advice.